myelodysplastic syndromes (MDS) | Page 174 | Aplastic Anemia & MDS International Foundation Return to top.

myelodysplastic syndromes (MDS)

Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare & Medicaid

Author(s): 
Giralt SA, Horowitz M, Weisdorf D, Cutler C
Primary Author: 
Giralt SA
Journal Title: 
J Clin Oncol
Original Publication Date: 
Jan 2011

Bone Marrow Disease(s): 

Continued azacitidine therapy beyond time of first response improves quality of response in patients with higher-risk myelodysplastic syndromes.

Author(s): 
Silverman LR, Fenaux P, Mufti GJ, Santini V, Hellström-Lindberg E, Gattermann N, Sanz G, List AF, Gore SD, Seymour JF
Primary Author: 
Silverman LR
Journal Title: 
Cancer
Original Publication Date: 
Jan 2011

BACKGROUND:

In the AZA-001 trial, azacitidine (75 mg/m(2)/d subcutaneously for Days 1-7 of every 28-day cycle) demonstrated improved survival compared with conventional care regimens in patients with International Prognostic Scoring System-defined intermediate-2- or high-risk myelodysplastic syndrome and World Health Organization-defined acute myeloid leukemia with 20% to 30% bone marrow blasts.
METHODS:

This secondary analysis of the AZA-001 phase 3 study evaluated the time to first response and the potential benefit of continued azacitidine treatment beyond first response in responders.
RESULTS:

Bone Marrow Disease(s): 

Myelodysplastic syndromes.

Author(s): 
Greenberg PL, Attar E, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Foran JM, Gaensler K, Garcia-Manero G, Gore SD, Head D, Komrokji R, Maness LJ, Millenson M, Nimer SD, O'Donnell MR, Schroeder MA, Shami PJ, Stone RM, Thompson JE, Westervelt P
Primary Author: 
Greenberg PL
Journal Title: 
J Natl Compr Canc Netw
Original Publication Date: 
Jan 2011

Overview The

Bone Marrow Disease(s): 
Share with addtoany.com.